VANFLYTA ® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3 -ITD Positive AML
Daiichi Sankyo’s (TSE: 4568) VANFLYTA® (quizartinib) has been approved in the European Union (EU) for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3-ITD positive.
VANFLYTA is the first FLT3 inhibitor approved in the EU specifically for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which represents about 25 to 30% of all new AML cases.1,2
The authorization by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on the results of the QuANTUM-First trial, which were published in The Lancet. In QuANTUM-First, VANFLYTA combined with standard cytarabine and anthracycline induction and standard cytarabine consolidation, and continued as maintenance monotherapy following consolidation, demonstrated a 22% reduction in the risk of death compared to standard chemotherapy alone (HR = 0.78 [95% CI: 0.62-0.98; p=0.032]) in patients with newly diagnosed FLT3-ITD positive AML. Median overall survival was 31.9 months for patients receiving VANFLYTA (n=268; 95% CI: 21.0-NE) compared to 15.1 months for patients in the control arm (n=271; 95% CI: 13.2-26.2) at a median follow-up of 39.2 months.
“This approval of VANFLYTA represents an important advancement for frontline treatment of patients with FLT3-ITD positive acute myeloid leukemia, an aggressive and historically difficult-to-treat subtype,” said Richard F. Schlenk, MD, Professorand Head of the Trial Center of the National Center of Tumour Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany. “VANFLYTA is a potent and selective FLT3 inhibitor that significantly improved overall survival when added to standard chemotherapy and it will be a valuable treatment option for newly diagnosed FLT3-ITD positive AML.”
“This approval of VANFLYTA is very welcome news for eligible patients diagnosed with FLT3-ITD positive AML each year,” said Samantha Nier, Network Director, Acute Leukemia Advocates Network (ALAN). “New medicines and treatment approaches are needed to help patients with this difficult type of leukemia live longer, and we look forward to VANFLYTA becoming available in countries throughout the EU.”
The safety profile of VANFLYTA in QuANTUM-First was consistent with previous clinical trials with no new safety signals observed. The most common grade 3 or 4 treatment emergent adverse events (occurring in ≥ 10% of patients) were febrile neutropenia (43%), hypokalemia (19%), neutropenia (18%) and pneumonia (11%). QTcF > 500 ms occurred in 2.3% of patients receiving VANFLYTA and 0.8% of patients discontinued VANFLYTA due to QT prolongation. Ventricular arrhythmia events with VANFLYTA were uncommon. Two (0.8%) patients receiving VANFLYTA experienced cardiac arrest with recorded ventricular fibrillation on ECG (one with fatal outcome), both in the setting of severe hypokalemia.
“With the approval of VANFLYTA in the European Union, patients diagnosed with FLT3-ITD positive acute myeloid leukemia may for the first time receive a targeted therapy developed and approved specifically for their disease subtype,” said Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc. “VANFLYTA is the second innovative medicine from our oncology pipeline approved in the EU and its successful development reflects our commitment to creating new standards of care for patients with cancer.”
QuANTUM-First is a randomized, double-blind, placebo-controlled, global phase 3 study evaluating VANFLYTA in combination with standard induction and consolidation therapy, including hematopoietic stem cell transplant (HSCT), and as maintenance monotherapy, in adult patients aged 18-75 with newly diagnosed FLT3-ITD positive AML. Patients were randomized 1:1 to receive VANFLYTA or placebo combined with cytarabine and anthracycline induction and cytarabine consolidation chemotherapy followed by up to three years of treatment with single-agent maintenance.
The primary study endpoint was overall survival. Secondary endpoints include event-free survival, post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3-ITD measurable residual disease negativity. Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints including duration of CR also were evaluated.
QuANTUM-First enrolled 539 patients at 193 study sites in 26 countries across Asia, Europe, North America, Oceania and South America. For more information, visit ClinicalTrials.gov.
About FLT3-ITD Positive Acute Myeloid Leukemia
More than 474,500 new cases of leukemia were reported globally in 2020 with more than 311,500 deaths.3 AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults.4,5 In Europe, approximately 18,000 people are diagnosed with AML each year and the five-year survival rate is reported at 17% for adult patients.6,7
A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common.8 Approximately 80% of FLT3 mutations are FLT3-ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis including increased risk of relapse and shorter overall survival.1,2 FLT3-ITD mutations occur in about 25% of all AML cases, with frequency reported as high as 30%.1,2
VANFLYTA is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.2
VANFLYTA is approved in the EU in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by VANFLYTA single-agent maintenance therapy for adult patients with newly diagnosed AML that is FLT3-ITD positive.
VANFLYTA is approved in the U.S. in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive as detected by an FDA-approved test. VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.
VANFLYTA also is approved in Japan for the treatment of AML that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for adult patients with newly diagnosed FLT3-ITD positive AML and as a monotherapy for relapsed/refractory AML that is FLT3-ITD positive as detected by an approved test. VANFLYTA is an investigational medicine in all countries outside of Europe, Japan and the U.S.
About the VANFLYTA Clinical Development Program
The VANFLYTA clinical development program includes a phase 1/2 trial in pediatric and young adult patients with relapsed/refractory FLT3-ITD positive AML in Europe and North America and several phase 1/2 combination studies as part of a strategic collaboration with The University of Texas MD Anderson Cancer Center.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com
1 Daver N, et al. Leukemia. (2019) 33:299-312.
2 Patel JP, et al N Engl J Med. (2012) Mar 22;366(12):1079-89.
3 Global Cancer Observatory. Population Fact Sheet: World. Updated March 2021.
4 American Cancer Society:Key Statistics for Acute Myeloid Leukemia. Updated January 2023.
5 Dong Y, et al. Exp Hematol Oncol. (2020);9:14.
6 Rodriguez-Abreu D, et al. Ann Oncol (2007);18 Suppl 1:i3-i8.
7 Heuser M, et al. Ann Oncol. (2020) 31(6):697-712.
8 Kennedy VE, et al. Front Onc. 23 December 2020;10. Volume 10 – 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Daiichi Sankyo, Inc.
+1 908 900 3183 (mobile)
Daiichi Sankyo Co., Ltd.
+81 3 6225 1126 (office)
Daiichi Sankyo Europe GmbH
+49 (89) 78080 (office)
Investor Relations Contact:
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reibus International Announces CEO Transition29.11.2023 20:00:00 CET | Press release
Reibus International, the world’s largest online marketplace for metals, announces the appointment of Temy Mancusi-Ungaro as its new Interim Chief Executive Officer. The decision to bring Temy on board reflects a new era of investment in the company and Reibus’ continued commitment to driving innovation and growth in the metals industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129023580/en/ Temy Mancusi-Ungaro (Photo: Business Wire) With over 17 years of experience in the B2B Software industry, Temy is a seasoned operator who brings a proven track record of scaling innovative B2B companies, including Reachdesk, Electric, Yext, and CityGrid. He most recently held the position of CEO at Reachdesk, where his acumen for navigating the complexities of scaling a business led the company to be named among the top 100 fastest-growing products, according to G2, for three years in a row. "We are thrilled to welcome Temy to t
Tongxin Micro Making a Splash at TRUSTECH, and Unveiling the World’s First eSIM Solution Tailored for Smart POS Systems29.11.2023 18:00:00 CET | Press release
November 28th marks the grand opening of TRUSTECH 2023 in Paris, France. Tongxin Micro, an industry-leading semiconductor solution provider, makes an impressive debut, showcasing its technological advancements in identity recognition, telecommunications, and financial payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129462718/en/ (Photo: Business Wire) In the realm of identity recognition, Tongxin Micro brings its document chip solutions in compliance with international ICAO standards that boast the highest security levels globally, catering to such applications as seafarer’s passport and official passport. In telecommunications, a full array of products and terminal applications are displayed, including standard SIM, SWP-SIM, digital car keys based on SWP-SIM, and eSIM wearable devices. In the payment sector, Tongxin Micro’s innovative payment technologies draw significant attention, ranging from chip application
Gillette Gaming launches new creative concept, Hit Reset with Gillette, to encourage and inspire gamers and fans worldwide29.11.2023 17:15:00 CET | Press release
For over ten years, GilletteTM, the world’s largest male grooming company, has been helping gamers look and play their best, whether it be for gaming or everyday life. This year, Gillette is refreshing its approach and creating a new era of gaming with its newest campaign, “Hit Reset with Gillette” – encouraging the gaming community to hit reset after a night of gaming, come back a better player and look sharp for the day with a fresh shave. Hitting “reset” is a universal term in gaming and works perfectly with grooming – inviting gamers and fans to start their day looking and feeling their best, to be their best and most confident, whether it be in gaming or whatever the day has ahead. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129843095/en/ (Graphic: Business Wire) To further inspire the gaming community, Gillette will leverage its Gillette Gaming Alliance to create “Hit Reset with Gillette” content and host branded
Kahuna Workforce Solutions Secures $21 Million in Series B Funding from Resolve Growth Partners to Advance Skills Management Technology for Frontline Workers29.11.2023 17:08:00 CET | Press release
Kahuna Workforce Solutions, the leading provider of operational skills and competency management software, today announced a $21 million Series B funding round led by Resolve Growth Partners. This investment marks a significant milestone in Kahuna’s growth journey and solidifies the criticality of skills management for industries with technical frontline workforces. As organizations navigate an ever-evolving and complex landscape, understanding, validating, and aligning workforce skills to strategic business objectives is central to operating at the highest level. Kahuna is at the forefront of skills management technology, equipping organizations with actionable skill insights for effective assessment, training and development, and staffing and deployment initiatives, ultimately enabling resilient operations, improved productivity, and a more competitive workforce. Kahuna’s customer base of leading Fortune 500 energy, manufacturing, and field service organizations, and world-renowned h
OPP SCIENCE Reaffirms Its Commitment to Public Security by Supporting the AGIR Meetings Sponsored by French National Gendarmerie29.11.2023 16:45:00 CET | Press release
OPPSCIENCE, a leader in Intelligence Analysis Management (IAM), reaffirms its support for public security by sponsoring the AGIR event. Following the introduction of its latest version of SPECTRA, a software dedicated to law enforcement, during Milipol Paris, OPPSCIENCE contributes to accelerating the initiatives of the National Gendarmerie on the seek of innovations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129543708/en/ The encounters at AGIR supported by OPPSCIENCE (Photo: Business Wire) MEETINGS AT AGIR: UNDERSTANDING THE NEEDS OF THE GENDARMERIE FOR LAW ENFORCEMENT Strengthening the dialogue between law enforcement and the technology industry is the goal of the AGIR exhibition (Accompagnement par la Gendarmerie de l’Innovation, de l’Industrie et de la Recherche). Initiated by the innovation unit of the National Gendarmerie, this exhibition enables innovators in the Gendarmerie community, specialized units, proj